Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
- 1 November 1998
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 12 (16) , 2161-2167
- https://doi.org/10.1097/00002030-199816000-00011
Abstract
To investigate the factors related to viral load becoming undetectable among patients from Southern Alberta who started a protease inhibitor for the first time, and to determine the factors related to subsequent re-emergence of detectable viral load amongst those patients whose viral load initially became undetectable. A total of 243 patients from the Southern Alberta Clinic had started a protease inhibitor for the first time and had been followed up for a median time of 32 weeks. Standard survival techniques including Kaplan-Meier techniques and Cox proportional hazards models were used to determine which factors were related to viral load becoming undetectable. At 24 weeks after first exposure to a protease inhibitor, 52.8% of the patients [95% confidence interval (CI), 45.2–56.6] had achieved an undetectable viral load. In a multivariate analysis, those with a higher initial viral load were less likely to become undetectable [relative hazard (RH), 0.50; 95% CI, 0.35–0.70; P P A significant proportion of patients in a routine clinic setting achieved an undetectable viral load measurement after first starting a protease inhibitor; viral load in patients with a higher CD4 cell count was more likely to become and stay undetectable. There was no evidence that patients who were drug-naive experienced significantly worse virological effects than drug-experienced patients, as long as the same number of new drugs was started at the date of first exposure to a protease inhibitor. Further follow-up of these patients is warranted to study the longer term effects of treatment with protease inhibitors.Keywords
This publication has 15 references indexed in Scilit:
- A Critical Assessment of the Prognostic Value of HIV-1 RNA Levels and CD4+ Cell Counts in HIV-Infected PatientsArchives of internal medicine (1960), 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- Prognostic Indicators for AIDS and Infectious Disease Death in HIV-Infected Injection Drug UsersJAMA, 1998
- Use of Changes in Plasma Levels of Human Immunodeficiency Virus Type 1 RNA to Assess the Clinical Benefit of Antiretroviral TherapyThe Journal of Infectious Diseases, 1998
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panelPublished by American Medical Association (AMA) ,1997
- Hidden dangers of incompletely suppressive antiretroviral therapyThe Lancet, 1997
- British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1997
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996